Introduced
by
To impose a new mandate on manufacturers of prescription drugs, to file detailed reports with the state on the costs associated with developing and marketing prescription drugs whose wholesale cost is more than $40 for a course of treatment. The bill would also create a state prescription drug commission comprised of individuals representing specified interests to determine whether a drug price increase is “unconscionable,” and if so recommend the manufacturer be investigated for violating the state consumer protection act.
Referred to the Committee on Health Policy
